Poolbeg Pharma #POLB August 2023 – CEO Jeremy Skillington talks to Alan Green

Poolbeg CEO Jeremy Skillington talks to Alan Green in this August 2023 interview, and explains the company’s ‘capital light’ model that is giving the group a real market advantage. Jeremy then covers the developments this year with Poolbeg’s flagship POLB001 asset towards a blockbuster treatment for severe influenza, and the expansion of application into oncology […]

Poolbeg Pharma #POLB – Influenza Artificial Intelligence model build completed & on track to deliver outputs in Q2 2023

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that, further to its announcement in March 2022 , the construction of the computational artificial intelligence (AI) influenza disease model has been completed by CytoReason Limited (‘CytoReason’), indicating that it […]

Poolbeg Pharma #POLB – Interim results for the six months to 30 June 2022

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces its unaudited interim results for the six months to 30 June 2022. Financial & Operational Highlights • Well capitalised with a strong cash balance of £18.9m as at 30 June […]